Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients

Stroke

Volumn 33, Issue 7, 2002, Pages 1763-1771

  Di Napoli, Mario ^a   Papa, Francesca ^a  

^a Casa di Cura Villa Pini d'Abruzzo ^*  (Italy)

Author keywords

C reactive protein; Fibrin D dimers; Inflammation; Stroke, ischemic; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; TICLOPIDINE; WARFARIN;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFICACY; FEMALE; HEMOSTASIS; HUMAN; INFLAMMATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SECONDARY PREVENTION; SEX DIFFERENCE; SMOKING; SURVIVAL; THROMBOSIS; VASCULAR DISEASE;

AGED; ANTICOAGULANTS; BIOLOGICAL MARKERS; BRAIN; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DISEASE-FREE SURVIVAL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYTIC AGENTS; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; TIME; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0036314321     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000019124.54361.08     Document Type: Article

References (35)

1. Treatment and secondary prevention of stroke: Evidence, costs, and effects on individuals and populations
2. Survival and recurrence following stroke: The Framingham Study
3. Long-term risk of recurrent stroke after a first-ever stroke: The Oxfordshire Community Stroke Project
4. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis
5. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis
6. Pathobiology of ischaemic stroke: An integrated view
7. Cytokines and adhesion molecules in stroke and related diseases
8. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
9. Low-grade acute-phase reactions on arteriosclerosis and the consequences for hemostatic risk factors
10. Hemostatic markers in acute ischemic stroke: Association with stroke type, severity, and outcome
11. Activated coagulation/fibrinolysis system and platelet function in acute thrombotic stroke patients with increased C-reactive protein levels
12. Antigenic markers on fragment DD, a unique plasmic derivative of human crosslinked fibrin
13. Regulation of fibrinogen and fibrin: And indirect feedback pathway
14. A linkage between the hemostatic and immune systems embodied in the fibrinolytic release of lymphocyte suppressive peptides
15. IL-6 functions as an exocrine hormone in inflammation: Hepatocytes undergoing acute phase responses require exogenous IL-6
16. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1β, IL-6 and plasminogen activator inhibitors from monocytes in vitro
17. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men
18. Fibrin D-dimer, tissue plasminogen activator, tissue plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study
19. C-reactive protein, fibrin D-dimer, and incident ischemic heart disease in the Speedwell study: Are inflammation and fibrin turnover linked in pathogenesis?
20. Thrombogenic factors and recurrent coronary events
21. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
22. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease
23. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies
24. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke
25. C-reactive protein in ischemic stroke: An independent prognostic factor
26. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid and mannose binding protein in human serum
27. Atherosclerosis: An inflammatory disease
28. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study 1984 to 1992
29. A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE)
30. Inflammation, statins, and outcome after ischemic stroke
31. Persistent inflammatory response in stroke survivors
32. Effect of plasma fibrinogen concentration on the inhibition of platelet aggregation after ticlopidine compared with aspirin
33. Therapeutic benefit: Aspirin revisited in light of the introduction of clopidogrel
34. Arachidonic acid as a bioactive molecule